FDA is reportedly shunning advisory committees.
Concerns from drugmakers, patients, and doctors.
Potential implications for drug approval processes.
Strategic angle: Growing worries about the FDA's diminishing use of advisory committees for public discourse.
FDA is reportedly shunning advisory committees.
Concerns from drugmakers, patients, and doctors.
Potential implications for drug approval processes.